Paclitaxel (Taxol)

Paclitaxel is a drug used experimentally in mesothelioma treatment. It may be an effective substitute for pemetrexed (Alimta) in pleural mesothelioma chemotherapy. Some peritoneal mesothelioma patients have benefited from follow-up paclitaxel treatments after surgery.

Written By

Edited By

Medical Review By

This page features: 11 cited research articles

Paclitaxel is approved by the U.S. Food and Drug Administration (FDA) for use against breast cancer, non-small cell lung cancer, ovarian cancer, AIDS-related Kaposi’s sarcoma and pancreatic cancer.

Doctors also use it as an experimental or off-label treatment for bladder cancer, esophageal cancer, melanoma, prostate cancer and mesothelioma. Paclitaxel is commonly given in combination with cisplatin or carboplatin.

Paclitaxel is an antimicrotubule agent. Microtubules are an essential part of the process by which cells divide. Paclitaxel binds to proteins in cell microtubules, which forces cells to stop dividing. Since cancer cells divide rapidly, their microtubules are a good target for chemotherapy.

This drug dates back to the late 1960s, when it was discovered in the bark of the Pacific yew tree. Researchers recognized its potential as an anti-cancer agent, but its natural scarcity made it difficult to market.

More than 20 years later, researchers found a way to produce paclitaxel synthetically. Bristol-Myers Squibb began marketing it as Taxol.

In 2005, the FDA approved a new type of the drug called nanoparticle albumin-bound paclitaxel, or nab-paclitaxel. In this formulation, the drug is contained in tiny particles of protein. This improves drug delivery and reduces side effects. Celgene Corporation markets nab-paclitaxel as Abraxane.

Drug Fast Facts

Paclitaxel Information

Name

Taxol, Abraxane

Manufacturer

Bristol-Myers Squibb, Celgene

Medical Code

J9267

Dosage

135 mg/m²

Administration Route

Intravenous or intraperitoneal

Active Ingredient

Paclitaxel

Drug Class

Antineoplastic agent, antimicrotubule agent

Related Drug

Docetaxel

Alternate Names

Anzatax, Asotax, Bristaxol, Onxol, Praxel

Interacting Drug

Adenovirus types 4 and 7 live, antihistamines, apalutamide, eluxadoline, idarubicin, idelalisib, influenza virus vaccine trivalent, ivacaftor, nefazodone, opiates, palifermin, quinidine

Medical Studies

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

FDA Warning

Skin problems, hives, acute allergic reaction characterized by breathing difficulty and low blood pressure

Find the Best Mesothelioma Treatment

Our patient advocates can help connect you with the nation's top mesothelioma doctors and cancer centers.

Get Free Help Now

Paclitaxel for Pleural Mesothelioma

In the 1990s, studies of paclitaxel (Taxol) as a single agent for pleural mesothelioma showed little effectiveness. Now researchers are testing nab-paclitaxel (Abraxane) in combination with other drugs.

A 2016 study published in Respirology Case Reports described one medical team’s success substituting nab-paclitaxel for pemetrexed.

Standard chemotherapy for mesothelioma combines pemetrexed with cisplatin or carboplatin, but pemetrexed is too toxic for some patients. In the case report, a pleural mesothelioma patient responded well to nab-paclitaxel with carboplatin after standard chemotherapy had failed.

In 2017, Clinical Cancer Research published the results of a laboratory experiment using mesothelioma cells. The researchers combined nab-paclitaxel with an experimental immunotoxin called RG7787, with good results.

That same year, Biomedicine & Pharmacotherapy reported on a novel drug delivery method for mesothelioma. The laboratory experiment involved loading paclitaxel into a special type of cell to help the drug reach cancer cells.

Paclitaxel for Peritoneal Mesothelioma

Paclitaxel also shows promise for peritoneal mesothelioma, according to a 2017 review in the European Journal of Surgical Oncology. The review was co-authored by Dr. Paul Sugarbaker.

Sugarbaker helped pioneer the technique of rinsing a patient’s abdomen with chemotherapy during surgery. This procedure is called hyperthermic intraperitoneal chemotherapy (HIPEC). It is associated with much longer survival times for peritoneal mesothelioma patients.

In the 2017 review, Sugarbaker’s team reported that outcomes are the best for patients who also get long-term paclitaxel. In these follow-up treatments, the drug is delivered to their abdomen to prevent cancer reoccurrence.

Side Effects of Paclitaxel

Like most chemotherapy drugs, paclitaxel damages healthy cells in addition to cancer cells. Side effects are usually worst about 15 to 21 days after treatment.

Common side effects of paclitaxel:

  • Low red- and white-blood-cell counts
  • Hair loss
  • Joint and muscle pain
  • Numbness and tingling in extremities
  • Nausea and vomiting
  • Diarrhea
  • Mouth sores
  • Severe allergic reaction

Rare side effects of paclitaxel:

  • Swelling in feet or ankles
  • Liver problems
  • Low blood pressure
  • Skin darkening at radiation treatment sites
  • Nail discoloration

Locate the Best Mesothelioma Doctor for You

Find a Specialist
Asbestos.com Mesothelioma Packet

Learn All About Mesothelioma Treatment

Order Your Free Guide

Find a Clinical Trial Near You

Get Help Now

Find a Mesothelioma Doctor

Get Your Free Treatment Guide

Locate a Clinical Trial

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?


Karen Selby, RN and Patient Advocate at The Mesothelioma Center

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators. Read More

Reviewed by placeholder

Medical Review By

Last Modified June 1, 2018
Sources
  1. U.S. National Library of Medicine. (2017, November 4). Paclitaxel.
    Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/paclitaxel#section=Top
  2. Sugarbaker, P. and Chang, D. (2017, July). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28189456
  3. Petrella, F. et al. (2017, March). Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28153512
  4. Zhang, J. et al. (2017, March). Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/27635089
  5. Kanai, O. et al. (2016, January). Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
    Retrieved from: http://onlinelibrary.wiley.com/doi/10.1002/rcr2.145/pdf
  6. National Cancer Institute. (2014, September 18). Paclitaxel.
    Retrieved from: https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel
  7. MedlinePlus. (2011, February 1). Paclitaxel Injection. #
    Retrieved from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607070.html
  8. Stephenson, F. (2002). A Tale of Taxol.
    Retrieved from: http://www.rinr.fsu.edu/fall2002/taxol.html
  9. Vogelzang, N. et al. (1999). High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
    Retrieved from: http://www.gnmhealthcare.com/pdf/01-2007/10/1240718_HighdosepaclitaxelplusGCS.pdf
  10. Van Meerbeeck, J. et al. (1996). Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/pdf/brjcancer00022-0129.pdf
  11. Chemocare. (n.d.). Paclitaxel. Retrieved from: http://chemocare.com/chemotherapy/drug-info/Paclitaxel.aspx

View our resources for patients and families

Get Help Today
Chat live with a patient advocate now loading spinner